Rega

SID MASHBURN AND ANN MASHBURN OPEN ON MADISON AVENUE

Retrieved on: 
Tuesday, August 29, 2023
Laguiole, Monocle, PT01, Tailor, Junghans, Clothing, Rega, Mashburn, Sid Mashburn, Commerce, J.Crew, Madison Avenue, Diadora, Jewellery, Ralph Lauren, Jackson Heights–Roosevelt Avenue/74th Street station, Shoe, Fashion design, Interior design, Timex, Saphir

NEW YORK, Aug. 29, 2023 /PRNewswire/ -- Ann and Sid Mashburn reopened the doors of their newly renovated and carefully curated Mashburn store on Madison Avenue on Thursday, August 3.

Key Points: 
  • NEW YORK, Aug. 29, 2023 /PRNewswire/ -- Ann and Sid Mashburn reopened the doors of their newly renovated and carefully curated Mashburn store on Madison Avenue on Thursday, August 3.
  • The store is located at 926 Madison Avenue, at the southwest corner of Madison Avenue and 74th Street on Manhattan's Upper East Side.
  • While it shares a single entrance, the store is divided between the Sid Mashburn men's brand and the Ann Mashburn women's brand.
  • Ann Mashburn
    In addition to their New York City store, Mashburn has locations in Atlanta, GA; Dallas, TX; Houston, TX; and Washington D.C., with a Sid Mashburn shop location in Los Angeles, CA.

Koresummit Winds Up Cannabis October Reinforcing the Importance of the Ecosystem

Retrieved on: 
Friday, October 21, 2022
ACH, CAGR, GLOBE, Real estate, Rega, Acquisition, USD, CEO, Ecosystem

NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- KoreConX's KoreSummit | Pocket Sessions Empowering Growth starts next Monday, Oct. 24.

Key Points: 
  • NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- KoreConX's KoreSummit | Pocket Sessions Empowering Growth starts next Monday, Oct. 24.
  • The cannabis sector has already been growing steadily for the past few years.
  • "This sector can absolutely raise money as there is plenty of private capital available," says Oscar Jofre, CEO and co-founder at KoreConX.
  • KoreConX also maintains a large online library of educational content to help companies navigate their capital-raising journey.

KoreSummit in October Presents a New Format to Discuss the Cannabis Ecosystem

Retrieved on: 
Friday, October 7, 2022
Growth, Housing, Employment, CAGR, Rega, Oscar, Acquisition, CEO, Ecosystem, ACH, GLOBE, Cannabis, USD

NEW YORK, Oct. 07, 2022 (GLOBE NEWSWIRE) -- KoreConX announces its new edition of the KoreSummit - Empowering Growth, from Oct. 24 to 28.

Key Points: 
  • NEW YORK, Oct. 07, 2022 (GLOBE NEWSWIRE) -- KoreConX announces its new edition of the KoreSummit - Empowering Growth, from Oct. 24 to 28.
  • In daily one-hour pocket sessions, the cannabis vertical will be the spotlight.
  • Yesterday, President Joe Biden announced that all federal convictions for simple marijuana possession were to be pardoned.
  • KoreConX also maintains a large online library of educational content to help companies navigate their capital-raising journey.

BEBUZEE, INC. (OTC Pink: ENGA) Plans To File RegA Next Week

Retrieved on: 
Wednesday, July 6, 2022
Rega, Securities Act of 1933, Securities Exchange Act of 1934, Climate change, GLOBE, COVID-19, Growth, Company, Compliance, Investment, Lists of disasters, Internet, News, Form 10-K, OTC Markets Group, Television

Joseph Onyero, Chief Executive Officer of Bebuzee, Inc., said: We have completed the re-structuring of the Company and are taking steps to be fully audited, fully reporting, file a Form 10 and a RegA.

Key Points: 
  • Joseph Onyero, Chief Executive Officer of Bebuzee, Inc., said: We have completed the re-structuring of the Company and are taking steps to be fully audited, fully reporting, file a Form 10 and a RegA.
  • This will give shareholders more information and make the Company more transparent.
  • Bebuzees technology scans the worlds news, features and information flow to give its dedicated readers the best of the Internet in one place.
  • Snap cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

Partnership Strengthens Growing Industries Raising Private Capital

Retrieved on: 
Wednesday, June 29, 2022
Acquisition, CEO, FINRA, GLOBE, Ecosystem, Industry, Compliance, Partnership, Investment, Cannabis, Rega, Eye, Security (finance)

As KorePartners, Fundopolis, a FINRA Broker-dealer registered in all 50 states, is eager to make their expertise available to the whole private capital ecosystem.

Key Points: 
  • As KorePartners, Fundopolis, a FINRA Broker-dealer registered in all 50 states, is eager to make their expertise available to the whole private capital ecosystem.
  • Fundopolis is also part of the ecosystem for RegD, RegCF, and RegA+ offerings providing the FINRA broker dealer services to help companies raise capital.
  • Founded in 2016, KoreConX is the first secure, All-In-One platform that manages private companies' capital market activity and stakeholder communications.
  • For investor relations and fundraising, the platform enables private companies to share and manage corporate records and investments: it assists with portfolio management, capitalization table and shareholder management, virtual minute book, security registration, transfer agent services, and virtual deal rooms for raising capital.

KoreSummit Brings Medtech A+ Team to Help Companies Raise Up to $75 Million

Retrieved on: 
Monday, June 20, 2022
Transfer, Pantel, Regulation A, Technology, Compliance, CEO, Oscar Jofre, Research, Rega, Medtech, EDT, Investment, Acquisition, SEC, Jumpstart Our Business Startups Act, Century, ATS, GLOBE, Legal OnRamp, Medicine, Management, Security (finance), Accounting

KoreConX and KorePartners have put together the KoreSummit Medtech A+ Team, which aims at helping these companies raise capital compliantly using Regulation A (RegA+).

Key Points: 
  • KoreConX and KorePartners have put together the KoreSummit Medtech A+ Team, which aims at helping these companies raise capital compliantly using Regulation A (RegA+).
  • Historically, there have been limited paths for early and growth-stage medtech companies to raise capital, which makes Scott Pantel an enthusiast of RegA+.
  • Legendary medtech entrepreneur Manny Villafaa, Ph.D.Sc., Founder and CEO of Medical 21, sums it up: "Regulation A+ is the 21st Century way to raise capital".
  • Founded in 2016, KoreConX is the first secure, All-In-One platform that manages private companies' capital market activity and stakeholder communications.

KoreConX With Its All-in-One Platform Provides Infrastructure to Medical Funding Professionals

Retrieved on: 
Thursday, October 21, 2021
Compliance, Quality of life, Technology, Regulation, Ecosystem, Partnership, Medicine, Patient, FDA, List of life sciences, SEC, FINRA, Budget, Investment, Rega, CEO, Movement, U.S. Securities and Exchange Commission, Solution, Acquisition, GLOBE, Reg, Financial adviser, Security (finance)

Ourplatform provides control from the decision through the offering and also provides shareholder management, monetization of investments and other features like compliance requirements."

Key Points: 
  • Ourplatform provides control from the decision through the offering and also provides shareholder management, monetization of investments and other features like compliance requirements."
  • Medical Funding Professionals has built a value-added offering around Regulation A+ fundraising they call the Capital Planning Valuation StrategyTM (CPVS).
  • Life Science Intelligence and InvestAcq also joined KoreConX and Medical Funding Professionals to deliver the CPVS to life science verticalsmedtech, biotech, and pharma.
  • Founded in 2016, KoreConX is the first secure, All-In-One platform that manages private companies' capital market activity and stakeholder communications.

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

Retrieved on: 
Wednesday, September 1, 2021
UCB, Rega, ACE2, Euronext, Degenerative disease, Twitter, Rega Institute for Medical Research, Ghent University, Severe acute respiratory syndrome coronavirus 2, Viral load, Immune system, Innovation, KU Leuven, Disease, Central nervous system, Antibody, Alpha, Clinical trial, Infection, VIB, VHH, Radio, Safety, Patient, Solution, Gamma, COVID-19, Professor, Vaccine, Pharmaceutical industry

The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.

Key Points: 
  • The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.
  • The study will sequentially evaluate three different doses of intravenously administered XVR011 with the primary endpoint of proportion of patients with adverse events.
  • Secondary endpoints include viral load, need for oxygen supplementation, clinical score (8-point ordinal scale) and other measures of clinical activity.
  • ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapiesproviding broad protection against viral infections, including coronaviruses.

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

Retrieved on: 
Wednesday, September 1, 2021
UCB, Rega, ACE2, Euronext, Degenerative disease, Twitter, Rega Institute for Medical Research, Ghent University, Severe acute respiratory syndrome coronavirus 2, Viral load, Immune system, Innovation, KU Leuven, Disease, Central nervous system, Antibody, Alpha, Clinical trial, Infection, VIB, VHH, Radio, Safety, Patient, Solution, Gamma, COVID-19, Professor, Vaccine, Pharmaceutical industry

The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.

Key Points: 
  • The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.
  • The study will sequentially evaluate three different doses of intravenously administered XVR011 with the primary endpoint of proportion of patients with adverse events.
  • Secondary endpoints include viral load, need for oxygen supplementation, clinical score (8-point ordinal scale) and other measures of clinical activity.
  • ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapiesproviding broad protection against viral infections, including coronaviruses.

Cloudastructure Raises More Than $29 Million in First RegA+ Offering

Retrieved on: 
Tuesday, July 13, 2021
Data management, Security, Technology, Audio, Video, Software, Networks, Hardware, Articles, Security, Safety, Crime prevention, Video surveillance, Applications of computer vision, Surveillance, Physical security, Closed-circuit television, Rega, Warrant, UST

Cloudastructure , which provides cloud-controlled video surveillance systems to enterprises, announced today it has secured more than $29.6 million in crowd-sourced commitments from more than 10,000 investors and over $22 million in exercisable warrants in its first RegA+ offering.

Key Points: 
  • Cloudastructure , which provides cloud-controlled video surveillance systems to enterprises, announced today it has secured more than $29.6 million in crowd-sourced commitments from more than 10,000 investors and over $22 million in exercisable warrants in its first RegA+ offering.
  • Since the $29.6 million raise began, Cloudastructure has rapidly grown its sales and engineering development team ten-fold and intends to scale even more in the coming months to achieve its revenue goals.
  • Cloudastructure enables a unified view of multiple sites from any mobile device and delivers a 75% lower total cost of ownership than other systems.
  • Market leaders such as Boxabl and High Times trust Cloudastructure for motion and facial recognition/detection, anomaly detection, counting, automatic license plate reading, advanced analytics, and compliance.